Janssen Search
Search results
Championing Patient-Centric, Data-Driven Clinical Trials
Championing Patient-Centric, Data-Driven Clinical Trials The Question that Drives Clinical Trial Innovation One common question I receive as Janssen Clinical Innovation’s Global Team Lead is, “what will clinical trials look like in five years, 10 ...
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
Jun 03, 2023 United States CHICAGO, June 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI ® (teclistamab-cqyv), a first-in-class BCMAxCD3 ...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
Jun 14, 2024 RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median progression-free survival of 8.9 years 1 ...
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Jan 27, 2023 United States Study unblinded following recommendation of Independent Data Monitoring Committee RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE ...
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
Mar 19, 2024 United States This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV Titusville, NJ (March 19, 2024) – Johnson & Johnson today announced that the U.S. ...
Johnson & Johnson Submits Supplemental Biologics License Application and New Drug Application to U.S. FDA Seeking Approval of RYBREVANT® (amivantamab-vmjw) Plus Lazertinib for the Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Dec 21, 2023 United States Submissions supported by data from landmark Phase 3 MARIPOSA study, which showed statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated ...
Wendy Johnson and Her Hope for Disease Interception
Wendy Johnson and Her Hope for Disease Interception Madeline Johnson and her brother, Sterling. Brian and Wendy Johnson, Madeline’s father and mother. The memory is vivid. Wendy Johnson, a mother of two, and her family were on their way home from a ...
New Data from Phase 3 PAPILLON Study Show RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60% Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation-Positive NSCLC
Oct 21, 2023 Spain New Data from Phase 3 PAPILLON Study Show RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Resulted in 60 Percent Reduction in Risk of Disease Progression or Death in Patients with Previously Untreated EGFR Exon 20 Insertion Mutation ...
Diversity, Equity & Inclusion In Action
Diversity, Equity & Inclusion In Action Turning Data into Measurable, Viable Results Johnson & Johnson aspires to help eradicate racial and social injustice as a public health threat by eliminating health inequities for people of color. For this ...
Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
Apr 21, 2023 Belgium Approval for AKEEGA ® is based on results from the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study that includes the largest cohort to date of BRCA1/2-positive patients with untreated metastatic castration ...